Skip to content
  • 6,812 federal solicitations are open right now. How many of them are yours?
  • New solicitations are posted every day. The ones you never saw are the ones you cannot win.
  • Stop checking SAM.gov every morning. Let the contracts that fit your business come to you.
  • Tell Abierto what you sell in one sentence. AI reads every open solicitation for you.
  • Deadlines are short. Hear about a solicitation the day it is posted, not the week it closes.
  • Amendments move deadlines. Watch a solicitation and Abierto tells you when it changes.
  • See which contracts in your field are about to end, and who holds them today.
  • Plans from $39 a month. See your matches before you pay.
See plans
AbiertoGet started

Presolicitation

Fisher Scientific Reagents and Consumable Materials for Cell Therapy Manufacturing

26-008155

National Institutes of Health, National Institutes of Health Olao. In-Vitro Diagnostic Substance Manufacturing.

Awarded

Fisher Scientific Company L.L.C.

$24,259.60 obligated so far on USAspending

Get the next one like this from National Institutes of Health by email, the day it is posted.Find my opportunities

This one was awarded in 2026

13 like it are open now in in-vitro diagnostic substance manufacturing

All 13 open in in-vitro diagnostic substance manufacturing

Description

As published on SAM.gov.

NOTICE OF INTENT TO AWARD A SOLE SOURCE CONTRACT

Title: Fisher Scientific Reagents and Consumable Materials for Cell Therapy Manufacturing
Notice ID (POTS): 26-008155
Product Service Code (PSC): 6550 – In Vitro Diagnostic Substances, Reagents, Test Kits, and Sets
NAICS Code: 325413 – In-Vitro Diagnostic Substance Manufacturing
Place of Performance: National Institutes of Health
Clinical Center
Bethesda, MD 20892

Notice

The National Institutes of Health (NIH) Clinical Center intends to award a sole-source firm-fixed-price purchase order to Fisher Scientific for validated reagents and consumable materials required by the Center for Cellular Engineering (CCE) to manufacture FDA-regulated cell-based therapies for use in NIH clinical trials.

Requirement

The Center for Cellular Engineering (CCE) uses these reagents and consumable materials in the manufacture of FDA-regulated cell-based therapies for patients enrolled in clinical trials at the NIH Clinical Center. All materials have been validated for use in CCE manufacturing processes to ensure they consistently meet the quality standards required to produce safe and effective cell therapy products. Additionally, each material has been reviewed and approved by the CCE Quality Assurance Department, and substitution with alternative products would require extensive revalidation of manufacturing processes, resulting in increased costs, schedule delays, and potential impacts to patient care.

Sole-Source Rationale

The required reagents and consumables have been validated and approved for use in CCE manufacturing processes. Substituting alternate materials would require extensive requalification, increase costs, delay production, and negatively affect patient care. Fisher Scientific is the only vendor capable of providing the required validated materials and supporting documentation necessary for FDA-regulated manufacturing.

Authority

The intended sole-source acquisition is authorized under Federal Acquisition Regulation (FAR) 13.106-1(b)(1)(i), which permits solicitation from a single source when the Contracting Officer determines that only one source is reasonably available for an acquisition not exceeding the Simplified Acquisition Threshold.

Capability Statements

This notice is not a request for quotations or proposals. However, responsible sources that believe they can satisfy the Government's requirement may submit a written capability statement. The Government will evaluate all capability statements received; however, the determination not to compete this requirement remains solely within the Government's discretion.

Submission Instructions

Capability statements shall reference POTS 26-008155 and must be submitted electronically no later than August 13, 2026, at 6:00 P.M. Eastern Time (ET).

Point of Contact

Shasheshe Goolsby
Team Leader
Hospital and Laboratory Support Division
Office of Acquisitions and Logistics Management
National Institutes of Health
Email: shasheshe.goolsby@nih.gov

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

UEI
HE7NJQGP4ED6
CAGE
22527
Vendor location
Pittsburgh, PA
Contract
75N98026P01364, purchase order
Obligated
$24,259.60
Actions
1 between August 20, 2026 and August 20, 2026
Competition
Competed Under SAP, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
26-008155 Fisher Scientific Reagents and Consumable Materials for Cell Therapy Manufacturing
Match
solicitation number 26008155 equals the FPDS solicitation identifier; same awarding office 75N980 (high confidence)

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. August 4, 2026

    Presolicitation

    Due August 13, 2026 at 6:00 PM EDT. SAM.gov, notice 6300eb88fb754bab906800057e4f1f43

    1 revisions on SAM
    • August 4, 2026: publish, presolicitation

Points of contact